<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00731289</url>
  </required_header>
  <id_info>
    <org_study_id>3II Fuchs</org_study_id>
    <nct_id>NCT00731289</nct_id>
  </id_info>
  <brief_title>Gait Patterns After Intraarticular Treatment of Patients With Osteoarthritis of the Knee</brief_title>
  <official_title>Efficacy and Safety of Intra-Articular Injections of Durolane® in the Treatment of Osteoarthritis in the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philipps University Marburg Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Philipps University Marburg Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to analyse the difference of the functional and clinical outcome&#xD;
      after intraarticular treatment of patients with osteoarthritis of the knee with a single&#xD;
      injection of hyaluronan (HA) or Triamcinolone (TA) with respect to the quality of life during&#xD;
      the study period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Osteoarthritis (OA) is the most common chronic joint disease of the aging patient. The&#xD;
      primarily affected joints are the knee and hip. The progress of the disease has an important&#xD;
      influence on the patient´s life, including functional and social activities, body image and&#xD;
      emotional well being. Furthermore, socioeconomic aspects play an eminent role in the&#xD;
      treatment of osteoarthritis in joints.&#xD;
&#xD;
      In non-operative treatment, pain reduction and improved function are the primary goals. It is&#xD;
      important to distinguish between systemic and local therapeutic options. In the systemic&#xD;
      treatment, palliation of pain can be achieved by simple analgetics, non- steroidal&#xD;
      anti-inflammatory drugs and opioids. Local therapy can selectively treat the symptomatic&#xD;
      joint. Intraarticular application of different drugs by injection can be performed.&#xD;
      Glucocorticoids are the most commonly used intraarticular agents, which reduce pain and&#xD;
      improve function and well being. In recent years, the intraarticular use of different&#xD;
      hyaluronan (HA) products became more widely accepted. Hyaluronan is a physiological component&#xD;
      of the synovial fluid and cartilage matrix. It is responsible for the viscoelastic properties&#xD;
      of the synovial fluid. In osteoarthrotic joints, the molecular weight and the concentration&#xD;
      of endogenous HA are decreased compared with healthy joints. This implies a reduction of the&#xD;
      viscoelasticity of the synovial fluid. In order to restore this viscoelasticity, augment the&#xD;
      flow of the synovial fluid, normalise the synthesis and inhibit the degradation of endogenous&#xD;
      hyaluronan, an application of exogenous HA can be performed. The therapeutic effects and the&#xD;
      safety of intraarticular application of HA in the treatment of OA in the knee have been&#xD;
      demonstrated in several clinical trials. Until now there are only three studies that&#xD;
      objectively analysed few aspects of the functional outcome after treatment with HA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>visual analogue scale for pain (VAS)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>gait analysis</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single intraarticular injection of hyaluronan 3 ml (Durolane®, 20 mg/ml non-animal stabilized hyaluronic acid (NASHA) in buffered physiological sodium chloride solution pH 7 in one pre-filled glass syringe in sterile pack</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single intraarticular injection of triamcinolone 1 ml (Volon A10®, 10mg triamcinolone acetonide, 10mg/ml)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hyaluronic acid</intervention_name>
    <description>one intraarticular injection of hyaluronan (HA) 3 ml (Durolane®, 20 mg/ml non-animal stabilized hyaluronic acid (NASHA) in buffered physiological sodium chloride solution pH 7 in one pre-filled glass syringe in sterile pack</description>
    <arm_group_label>1</arm_group_label>
    <other_name>20 mg/ml non-animal stabilized hyaluronic acid (NASHA)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triamcinolone</intervention_name>
    <description>one intraarticular injection of triamcinolone 1 ml (Volon A10®, 10mg triamcinolone acetonide, 10mg/ml)&#xD;
antiinflammatory intervention</description>
    <arm_group_label>2</arm_group_label>
    <other_name>triamcinolone acetonide, 10mg/ml</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  men and women between 35 and 80 years of age&#xD;
&#xD;
          -  radiographically verified degenerative osteoarthritis of the knee (grade II or III&#xD;
             according to the Kellgren and Lawrence classification)&#xD;
&#xD;
          -  pain of at least 40 mm on a 100 mm visual analogue scale (VAS) at initial examination&#xD;
&#xD;
          -  persisting pain for at least 6 months&#xD;
&#xD;
          -  Lequesne-Score of at least 10 points&#xD;
&#xD;
          -  good physical and mental status&#xD;
&#xD;
          -  good compliance and agreement to participate in this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  non-degeneratively induced osteoarthritis&#xD;
&#xD;
          -  rheumatoid arthritis&#xD;
&#xD;
          -  ligamentous instability or complete resection of the meniscus&#xD;
&#xD;
          -  Sudeck´s disease&#xD;
&#xD;
          -  operations of the affected knee within the last three months&#xD;
&#xD;
          -  varus or valgus deformity of more than 15 degrees&#xD;
&#xD;
          -  patellofemoral arthritis&#xD;
&#xD;
          -  intraarticular therapy of the affected joint within the last 6 months with hyaluronan&#xD;
             and three months with glucocorticoids&#xD;
&#xD;
          -  severe systemic diseases (tumor, exacerbated diabetes mellitus, hyperthyroidism)&#xD;
&#xD;
          -  anti-thrombotic medication or regular medication with NSAID/psychiatric&#xD;
             pharmaceuticals&#xD;
&#xD;
          -  infectious diseases&#xD;
&#xD;
          -  alcohol abuse&#xD;
&#xD;
          -  drugs&#xD;
&#xD;
          -  psychiatric diseases or suicidal tendencies&#xD;
&#xD;
          -  involvement in another study&#xD;
&#xD;
          -  non-compliance&#xD;
&#xD;
          -  acute hemarthrosis or joint effusion&#xD;
&#xD;
          -  allergic predisposition&#xD;
&#xD;
          -  skin infections or skin diseases around the knee&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susanne Fuchs-Winkelmann, Prof. MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Marburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Orthopaedics, Movement Analysis Lab, University Hospital Münster, Germany</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <study_first_submitted>August 5, 2008</study_first_submitted>
  <study_first_submitted_qc>August 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2008</study_first_posted>
  <last_update_submitted>August 7, 2008</last_update_submitted>
  <last_update_submitted_qc>August 7, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2008</last_update_posted>
  <responsible_party>
    <name_title>Adrian Skwara</name_title>
    <organization>Department of Orthopaedics and Rheumatology, University Hospital Marburg</organization>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Knee</keyword>
  <keyword>Hyaluronan</keyword>
  <keyword>Gait Analysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Hyaluronic Acid</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

